Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917787 | 0.82 | CYP1A2 (0.54) | KDM4EMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL918646 | 0.82 | KDM4E (0.41) | KDM4EMAPK1MEN1KMT2ATSHR | |
| SCHEMBL2096433 | 0.81 | MEN1 (0.46) | KDM4EMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL2090327 | 0.77 | MEN1 (0.43) | KDM4EMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL2207645 | 0.72 | MEN1 (0.60) | KDM4EMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL918505 | 0.71 | MEN1 (0.37) | KDM4EMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL13067433 | 0.70 | CYP1A2 (0.46) | KDM4EMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL8104266 | 0.70 | CHRM2 (0.68) | KDM4EMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL5539688 | 0.69 | CCR4 (0.40) | KDM4EMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL8308417 | 0.69 | KDM4E (0.67) | KDM4EMEN1KMT2ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981131-B2 | Tricyclic compounds for the treatment of inflammatory disorders | Piramal Enterprises Limited (IN) | 2015-03-17 | — | — | US | claimed |
| US-20110009396-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2011-01-13 | — | — | US | claimed |
| WO-2009016565-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2009-02-05 | — | — | WO | claimed |
| US-8981131-B2 | Tricyclic compounds for the treatment of inflammatory disorders | Piramal Enterprises Limited (IN) | 2015-03-17 | — | — | US | disclosed |
| US-20110009396-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2011-01-13 | — | — | US | disclosed |
| WO-2009016565-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009396-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL1R1, IL1B, IL1A | KDM4E 4136/4885MAPK1 2058/4885MEN1 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.